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Abstract
Purpose Ulcerative colitis (UC) is associated with
impaired health-related quality of life (HRQL) and work-
related outcomes (WRO). This analysis examined corre-
spondences among measures of HRQL and WRO in
patients with UC, as well as the magnitude of each mea-
sure’s responsiveness to disease activity and treatment.
Methods An open-label, prospective trial of delayed-
release mesalamine tablets formulated with MMX tech-
nology included 8 weeks of treatment for patients with
active mild-to-moderate UC (n = 137) and 12 months of
maintenance treatment for patients with quiescent UC
(n = 206). Spearman correlations (q) measured inter-
domain associations across measures of generic HRQL
[12-item Short-Form Health Survey (SF-12v2)], disease-
specific HRQL [Short Inflammatory Bowel Disease Ques-
tionnaire (SIBDQ)], and disease-specific WRO [Work
Productivity and Activity Impairment for Specific Health
Problems (WPAI:SHP)]. Responsiveness to disease activ-
ity and treatment was assessed for each instrument.
Results Changes in scores from baseline to week 8 were
moderately correlated across all instrument domains: 65 of
80 (81 %) between-instrument inter-domain correlations
were of moderate magnitude (0.30 \ q\ 0.70), with an
average magnitude of 0.42 [95 % confidence interval (CI)
0.38–0.46]. Associations between symptom measures were
stronger for SIBDQ (|average q| = 0.41; 95 % CI
0.34–0.48) and WPAI:SHP (0.40; 0.30–0.47) than SF-12v2
(0.30; 0.27–0.34). SIBDQ was most sensitive to treatment
[effect size (dz) for change from baseline to week 8 = 0.62;
95 % CI 0.35–0.89], followed by WPAI:SHP (dz = 0.43;
0.32–0.54) and SF-12v2 (dz = 0.33; 0.27–0.39).
Conclusion While the SIBDQ showed the greatest overall
responsiveness to disease activity and treatment, all three
patient-reported outcomes instruments provided comple-
mentary interpretive information regarding the impact of
UC treatment.
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ANCOVA Analysis of covariance
ANOVA Analysis of variance
BP Bodily pain domain of the SF-12v2
BS Bowel symptoms domain of the SIBDQ
EF Emotional functioning domain of the SIBDQ
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HRQL Health-related quality of life
IBD Inflammatory bowel disease
IBDQ Inflammatory Bowel Disease Questionnaire
MH Mental health domain of the SF-12v2
MMX Multi Matrix System
PF Physical functioning domain of the SF-12v2
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RBS Rectal bleeding severity
RE Role emotional domain of the SF-12v2
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RP Role physical domain of the SF-12v2
SF Social functioning domain of the SF-12v2
SF-12v2 12-Item Short-Form Health Survey, version 2
SF-36 36-Item Short-Form Health Survey
SIBDQ Shortened Version of the Inflammatory
Bowel Disease Questionnaire
SIMPLE Strategies in Maintenance for Patients
Receiving Long-term Therapy study
SS Systemic symptoms domain of the SIBDQ
STF Stool frequency
UC Ulcerative colitis
WPAI Work Productivity and Activity Impairment
Questionnaire
WPAI:SHP Work Productivity and Activity Impairment
Questionnaire: Specific Health Problem
WRO Work-related outcomes
VT Vitality domain of the SF-12v2
Introduction
Ulcerative colitis (UC), an inflammatory bowel disease
(IBD), is marked by chronic inflammation of the large
intestine and rectum. Symptoms associated with UC
include fatigue, a constant urge to defecate, nausea, diar-
rhea, rectal bleeding, and abdominal pain. The frequency
and severity of these symptoms are closely linked to
impairments in patient-reported outcomes (PRO), includ-
ing health-related quality of life (HRQL) [1–7], and work-
related outcomes (WRO) such as increased rates of
absenteeism and work disability and decreased work pro-
ductivity [8–16].
Previous research on patients with UC shows improve-
ments in HRQL [17–22] and WRO [18, 23] following
treatment when accompanied by decreases in disease
activity. For example, both Irvine et al. [20] and Reinisch
et al. [23] reported that patients with UC who demonstrated
clinical response following treatment had significantly
better scores on generic and disease-specific measures of
HRQL [the 36-item Short-Form health outcomes survey
(SF-36) and the Inflammatory Bowel Disease Question-
naire (IBDQ), respectively] than non-responders. Further-
more, Reinisch et al. [23] found that clinical remission
predicted significantly greater improvements in work
attendance, and work productivity, and a decreased likeli-
hood of receiving disability benefits.
Cross-sectional studies of patients with UC have typically
found concordance between generic and disease-specific
HRQL [2, 23–25]. A cross-sectional study by Bernklev et al.
[26] that examined the simultaneous relations among generic
and disease-specific HRQL and WRO found that both IBDQ
and SF-36 scores predicted absenteeism and work disability
payments. Cross-sectional studies by Cohen et al. [10] and
Gibson et al. [11] found that HRQL (SIBDQ, SF-36) and
WRO [Work Productivity and Activity Impairment survey
(WPAI)] were associated with disease severity and fatigue,
respectively, in patients with UC. Given that few studies
have captured the simultaneous impact of treatment on dis-
ease-specific HRQL, generic HRQL, and WRO for patients
with UC, the degree to which these outcomes are interre-
lated, and the sensitivity and responsiveness of these out-
comes to treatment and disease activity have not been fully
established.
The current analysis examines associations among PRO
instruments measuring generic and disease-specific HRQL
[the 12-item Short-Form Health Survey, version 2 (SF-
12v2) and the Short IBDQ (SIBDQ), respectively] and
disease-specific WRO [the WPAI: Specific Health Problem
(WPAI:SHP)] as well as the extent to which these out-
comes are negatively associated with disease activity for
patients with mild-to-moderate UC who participated in an
open-label prospective trial of delayed-release mesalamine
tablets formulated with MMX (Cosmo Technologies Ltd,
Wicklow, Ireland) technology (hereafter referred to as
delayed-release mesalamine). The objective of the current
analysis is to test several hypotheses regarding the inter-
relation among these PRO measures, their relative sensi-
tivity to treatment, and their relative responsiveness to




Data included in the current analysis were collected from the
Strategies in Maintenance for Patients Receiving Long-term
Therapy (SIMPLE) study [27], a multicenter, prospective,
single-treatment, open-label trial (NCT00446849). This
study consisted of a screening period, followed by two
phases: an 8-week acute phase, and a 12-month maintenance
phase. Figure 1 presents a flowchart of the study design. A
more detailed description of the SIMPLE study has been
presented elsewhere [27].
Patients diagnosed with mild-to-moderate active UC at
screening were entered into the acute phase, where they
received daily MMX mesalamine 2.4–4.8 g/day for
8 weeks. Dose titration in increments of 1.2 mg was
implemented when necessary throughout the acute phase.
Data for all PRO instruments were collected at the acute
phase baseline and at the 8-week endpoint.
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Patients with quiescent UC at screening, as well as those
who achieved quiescence by the acute phase baseline, were
able to participate in the 12-month maintenance phase.1 In
this phase, patients received daily MMX mesalamine 2.4 g/
day for 12 months. Data for all PRO instruments were
collected from three onsite visits over the 12 months: at
baseline, 6, and 12 months (or early withdrawal).
This trial was approved by Institutional Review Boards
at each study site. Only patients who provided written




The SF-12v2 is a 12-item self-report survey of HRQL with
a 4-week recall period [28]. Item responses afford calcu-
lation of eight domains representing separate dimensions of
functional health and well-being: physical functioning
(PF), role physical (RP; role limitations due to physical
problems), bodily pain (BP), general health perceptions
(GH), vitality (VT), social functioning (SF), role emotional
(RE; role limitations due to emotional problems), and
mental health (MH). PCS and MCS scores are computed by
summing weighted domain scores. SF-12v2 domains and
summary scores were standardized using a T-score metric
(mean = 50, standard deviation = 10) based on a US
general population normative sample. Higher scores indi-
cate better health outcomes on all domains and summary
scores.
SIBDQ (disease-specific HRQL)
The SIBDQ [29] consists of 10 items chosen from among
the 32 items on the original IBDQ instrument. This
instrument has demonstrated good psychometric properties
(i.e., reliability, responsiveness, and construct and criterion
validity) in assessment of disease-specific HRQL within
the UC patient population [29–32]. The SIBDQ assesses
the impact of patients’ IBD symptoms on different aspects
of HRQL over the previous 2 weeks, as measured by four
domains: bowel symptoms (BS; calculated by summing
responses to three items capturing the frequency of
abdominal pain, gassiness, and feeling the urge to defe-
cate), systemic symptoms (SS; calculated by summing
responses to two items capturing the frequency of fatigue
and difficulty in maintaining weight), emotional function










MMX mesalamine 2.4 g/day 
once daily for 12 months 
Treated sample: n=208
PRO scores at baseline: n=203
PRO scores at Month 6: n=144
PRO scores at Month 12: n=157
PRO scores at both baseline and 
Month 12: n=130 
PRO scores at all visits: n=128
Acute Phase
MMX mesalamine 2.4 g/day-
4.8 g/day for 2 months
Treated sample: n=137
PRO scores at baseline: n=128
PRO scores at Week 8: n=109
PRO scores at both visits: n=103
Fig. 1 Flowchart of study design. UC ulcerative colitis, MMX Multi Matrix System, PRO patient-reported outcome
1 In the SIMPLE trial, quiescence was defined as no more than 1
additional bowel movement than normal and no rectal bleeding.
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capturing the frequency of depression, stress, and anger),
and social function (calculated by summing responses to
two items capturing the frequency of having to cancel
social activities, and being limited in social activities).
Responses to each item are also summed to create a total
SIBDQ score. Response options for each item range from 1
to 7; thus, possible scores range from 3 to 21 for BS and
social function domains, and from 2 to 14 for SS and EF
domains, with total scores ranging from 10 to 70. For all
domains and the total score, higher scores indicate better
health outcomes.
WPAI:SHP (WRO)
The WPAI:SHP consists of six items that can be used to
measure the impact of a person’s specific health problem
(in this case, UC) on WROs, including work time missed,
decreases in productivity, and impairment in daily non-
work-related activities (e.g., childcare) during the preced-
ing 7 days [33]. The WPAI:SHP has been psychometri-
cally validated within samples of patients with a variety of
gastrointestinal disorders, including gastroesophageal
reflux disease [34, 35], Crohn’s disease [36], and irritable
bowel syndrome [37].
For patients employed over the previous 7 days, four
domains were calculated based on item responses: absen-
teeism (the percentage of work time missed due to a
patient’s UC), presenteeism (the percentage of impairment
while working due to a patient’s UC relative to their work
productivity when healthy), overall work impairment (the
percentage of overall work impairment due to a patient’s
UC), and activity impairment (the percentage of impair-
ment in non-work activities due to a patient’s UC). Only
scores for the activity impairment domain were computed
for patients not employed in the previous 7 days. All
domain scores range from 0 to 100 %, with lower scores on
all domains signifying better WRO (i.e., less impairment).
UC symptoms
Two UC symptoms, stool frequency (STF) and rectal
bleeding severity (RBS), were measured using single-item
patient reports. Measures for each of these symptoms are
considered crucial for determining the status of disease in
patients with UC, as indicated by their inclusion in two
well-established measures of disease activity: the Ulcera-
tive Colitis Disease Activity Index (UC-DAI) [38] and the
Mayo score [39]. Previous research has found evidence that
STF and RBS items alone are sufficient to estimate disease
activity in patients with UC [40].
Patients provided once-daily responses on each via
telephone or Internet. For the STF item, patients indicated
whether their number of bowel movements that day was
the same or only 1 more than their normal frequency (0), 2
or 3 more than their normal frequency (1), or at least 4
more than their normal frequency (2). For the RBS item,
patients indicated whether they had no rectal bleeding in
their stool (0), streaks of blood in their stool (1), obvious
blood in their stool (2), or mostly blood in their stool (3) on
the current day. At the time of each on-site visit, the
patient’s three most recent responses to each of these items
were averaged to create a total score for each symptom.2
Lower scores on both measures indicate better outcomes.
Analysis plan
Patient baseline characteristics
Descriptive statistics (i.e., means and standard deviations
for continuous variables, frequencies and percentages for
categorical variables) were calculated for patient charac-
teristics (e.g., age, gender, and employment status) and
values of outcome measures for the full baseline sample of
patients in each of the acute and maintenance phases.
Descriptive statistics were also calculated separately at
maintenance phase baseline for two subsamples of patients
in the maintenance phase: those who were identified as
quiescent at screening and thus entered the maintenance
phase directly (maintenance phase-only subsample), and
those who were identified with active disease at screening
and thus only entered the maintenance phase after
achieving quiescence at the end of the acute phase
(acute ? maintenance phase subsample).
Baseline values of patient characteristics and outcome
scores were compared between maintenance phase-only
and acute ? maintenance phase subsamples to demonstrate
similarity between these subsamples to justify combining
both subsamples into a single analysis group. Comparisons
of SF-12v2, SIBDQ, and UC symptom scores between
these subsamples were conducted in previous analyses of
these data [19, 22]; comparisons of patient characteristics
and WPAI:SHP scores between the two groups were con-
ducted here. Comparisons between continuous variables
were conducted using independent samples t tests (two-
tailed), while comparisons between categorical variables
(gender, employment status) were based on Fisher’s exact
test (two-tailed).
Correspondence among PRO instruments
The objective of this analytic approach was to estimate the
strength of relations among outcomes captured by the three
PRO instruments. Analyses falling under this approach were
2 Scores were derived from multiple responses rather than from a
single response to reduce error and thus increase precision of scores.
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designed to test several hypotheses regarding the relative
magnitude of associations among PRO instruments.
Based on previous empirical findings described above,
and given the conceptual relatedness among each of these
outcomes, Hypothesis 1 was that changes in SF-12v2,
SIBDQ, and WPAI:SHP domain scores from baseline to
8-week endpoint during the acute phase would, in general,
be moderately correlated (i.e., most correlation coefficients
falling within the range of 0.3–0.7).
Since the WPAI:SHP measures a different construct
(WRO) than that shared by the other two instruments
(HRQL), Hypothesis 2 was that the average inter-domain
correlation between the SF-12v2 and the WPAI:SHP would
be smaller than the average inter-domain correlation
between the SF-12v2 and the SIBDQ.
Also, because the SIBDQ and WPAI:SHP are both
designed to capture the impact of disease-specific out-
comes, as opposed to generic health outcomes measured by
the SF-12v2, Hypothesis 3 was that the average inter-
domain correlation between SIBDQ and WPAI:SHP scores
would be larger than the average inter-domain correlation
between SF-12v2 and WPAI:SHP scores.
To test Hypotheses 1–3, we examined correlations
among changes in scores for all domains from each of the
three PRO instruments. Change scores for each PRO
domain were calculated by subtracting patients’ acute
phase baseline score from their acute phase 8-week end-
point score. Spearman correlation coefficients between all
change scores were computed to estimate the direction and
magnitude of associations.
To estimate the relative strength of associations among
each of the PRO instruments, we calculated the average inter-
domain correlation between each instrument pair using
Fisher’s method [41], which Monte Carlo simulations have
shown to produce less biased estimates of mean correlation
coefficients [42, 43] the following procedure. First, Spearman
coefficients were transformed into z-scores using Fisher’s r-








Next, the average z-score was computed as the sum of
all z-scores divided by the number of z-scores. Finally, the
average z-score was transformed back into the average
correlation coefficient using the inverse of Fisher’s r-to-z
transformation, based on the following equation:
r ¼ exp 2zð Þ  1
exp 2zð Þ þ 1 ð2Þ
For each correlation coefficient, a 95 % confidence
interval (CI) was calculated using the following procedure.
First, the correlation coefficient (q) was transformed into a
z-score (zq) using Fisher’s r-to-z transformation (Eq. 1).
Second, the standard error for zq was calculated using the
following equation: [41, 44]
SEzq ¼
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n  3p ð3Þ
Third, the 95 % CI for zq (95 % CIzq ) was calculated by
multiplying SEzq by 1.96. Fourth, the 95 % CIzq was
transformed into the 95 % CIq using the inverse of Fisher’s
r-to-z transformation (Eq. 2).
Responsiveness of PRO instruments to disease activity
and sensitivity to treatment
The objective of this analytic approach was to estimate the
relative degree to which changes in each of the three PRO
instruments corresponded to changes in UC symptoms (i.e.,
STF and RBS) over the course of treatment. Analyses
falling under this approach were designed to test hypoth-
eses regarding the responsiveness among instruments to
disease activity and their sensitivity to treatment.
Since both the SIBDQ and WPAI:SHP, but not the SF-
12v2, explicitly assess the impact of UC-related symptoms
on patient outcomes, Hypothesis 4 was that the correlations
between changes in SIBDQ and WPAI:SHP scores and
changes in UC symptoms would generally be larger than
correlations between changes in SF-12v2 scores and
changes in these symptoms.
Given previously established findings from this trial that
HRQL was lower for patients who experienced clinical
recurrence (based on the recurrence of symptoms) at the
12-month maintenance phase endpoint as compared to non-
recurrent patients [19, 22], and following the same logic of
the previous hypothesis, Hypothesis 5 was that differences
in change scores between recurrent and non-recurrent
patients would be relatively larger for the SIBDQ and
WPAI:SHP than for the SF-12v2.
Finally, because disease-specific HRQL captures more
proximally the impact of treatment on patient outcomes
than does generic HRQL or WRO, Hypothesis 6 was that
the SIBDQ would exhibit greater sensitivity to acute
treatment than would the SF-12v2 or WPAI:SHP.
The responsiveness of HRQL and WRO to disease
activity was captured using two analytic approaches. First,
the correspondences between changes in PRO domain
scores and changes in symptom scores during the acute
phase were examined using Spearman correlations. Change
scores for symptom measures were calculated by sub-
tracting each patient’s acute phase baseline score from their
acute phase 8-week endpoint score. To test the relative
strength of associations between the different PRO instru-
ments and the measures of disease activity in Hypothesis 4,
we calculated the average correlations across all domain
scores within each instrument with scores on each
Qual Life Res (2015) 24:671–683 675
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symptom measure using Fisher’s r-to-z transformation
procedure described above.
The responsiveness of each PRO instrument to changes
in disease activity was also assessed by comparing PRO
domain scores between patients who did or did not exhibit
clinical recurrence at the 12-month maintenance phase
assessment. Patients were classified as exhibiting clinical
recurrence if they reported 4 or more bowel movements per
day above their normal frequency and the presence of
rectal bleeding, urgency to defecate, or abdominal pain.
Univariate analysis of covariance (ANCOVA) models,
with recurrence status as a between-subjects’ factor and
patients’ age, gender, body mass index (BMI), and main-
tenance baseline domain value as covariates, statistically
compared recurrent and non-recurrent patients on each
instrument domain. Cohen’s d effect sizes [45] for stan-
dardized differences between independent-group estimated
means3 were calculated for all comparisons to indicate the
strength of the effect of classification group for each
domain score. Interpretation of these effects followed
Cohen’s conventional guidelines for interpretation of
magnitude (i.e., small effect size: d & 0.2, medium effect
size: d & 0.5, large effect size: d & 0.8) [45].
The sensitivity of each PRO instrument to acute treat-
ment was examined using paired-sample t tests to compare
mean scores between baseline and 8-week assessments.
Magnitude of change was estimated using Cohen’s dz
effect sizes [45] for standardized mean differences across
dependent samples.4
No imputation techniques were used for patients missing
data at a visit; only observed values were analyzed at each
time point. Average correlations and effect sizes were cal-
culated using Microsoft Excel (2007; Redmond, WA, USA).
All other statistical analyses were performed using SPSS for
Windows, version 17.0.2 (2009; Chicago, IL, USA).
Results
Patient baseline characteristics
Table 1 presents descriptive statistics for patients’ baseline
age, gender, and employment status; domain and summary
scores for the SF-12v2, SIBDQ, and WPAI:SHP; UC symp-
tom scores for the full sample of patients in each of the acute
and maintenance phases; and the maintenance phase baseline
values of the maintenance phase-only and acute ? mainte-
nance phase subsamples. Previously published comparisons
between these subsamples yielded no statistically significant
group differences for either SF-12v2, SIBDQ, or UC symp-
tom scores (all P [ 0.05) [19, 22]. Subsample comparisons of
patient characteristics and WPAI:SHP scores conducted here
found no statistically significant differences between the two
groups in gender distribution, employment status, or any
WPAI:SHP domains (all P [ 0.05), although a statistically
significant difference in age was observed (P \ 0.05), with
patients in the maintenance phase-only subsample being, on
average, 5.5 years older than those in the acute ? mainte-
nance phase subsample.
Correspondence among changes in PRO domain scores
during the acute phase
Spearman coefficients for inter-domain correlations among
baseline-endpoint changes in SF-12v2, SIBDQ, and
WPAI:SHP domain scores in the acute phase are presented in
Table 2. Inter-domain correlations across the three instru-
ments reflect mostly moderate associations, with the absolute
values for 65 out of the 80 inter-domain correlation coeffi-
cients (81 %) ranging between 0.30 and 0.70 [the absolute
values for the remaining 15 inter-domain correlation coeffi-
cients were small (B0.30)], with an average magnitude of
0.42 (95 % CI 0.38–0.46). The magnitude of correlation
coefficients between SF-12v2 and SIBDQ domain change
scores ranged from 0.24 to 0.70 [with absolute values for 28 of
the 32 (87.5 %) coefficients between 0.30 and 0.70, and
absolute values for the remaining four coefficients (12.5 %) at
0.30 or below], with an average magnitude of 0.44 (95 % CI
0.39–0.49); the magnitude of correlation coefficients between
SF-12v2 and WPAI:SHP domain change scores ranged from
0.07 to 0.57 [with absolute values for 23 of the 32 (71.9 %)
coefficients between 0.30 and 0.70, and with absolute values
for the remaining nine coefficients (28.1 %) at 0.30 or below],
with an average magnitude of 0.37 (0.31–0.42); and magni-
tude of correlation coefficients between SIBDQ and
WPAI:SHP domain change scores ranged from 0.13 to 0.68
[with absolute values for 14 of the 16 (87.5 %) coefficients
between 0.30 and 0.70, and absolute values for the remaining
two coefficients (12.5 %) at 0.30 or below], with an average
magnitude of 0.47 (0.36–0.59).
Responsiveness of PRO instruments to changes
in disease activity
Spearman correlation coefficients between acute phase
change scores of the PRO domains and symptoms measures
3 Cohen’s d effect sizes [45] were calculated using the following equa-
tion: d ¼ 2  f ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃg2=ð1  g2Þp , where g2 ¼ dfbetweensubjects  F =
dfbetweensubjects  F þ dferror
 
; and where F is derived from between-
subjects ANCOVA with recurrent status as an independent factor, and
age, gender, BMI, and maintenance baseline scale value as covariates.
4 Cohen’s dz effect sizes [45] were calculated using the following
equation:
dz ¼ ðM1  M2Þ=r12 ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðr1Þ2 þ ðr2Þ2½2  r12  r1  r2
q
; with
r12representing the correlation between scores at each time.
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are presented in Table 3. The magnitude of correlation
coefficients between changes in SF-12v2 domain and
changes in symptom measures ranged from 0.15 to 0.45
[with absolute values for 9 of the 16 (56.3 %) coefficients
between 0.30 and 0.70, and absolute values for the
remaining seven coefficients (43.8 %) at 0.30 or below],
with an average magnitude of 0.30 (95 % CI 0.27–0.34); the
magnitude of correlation coefficients between changes in
SIBDQ and changes in symptom measures ranged from
0.26 to 0.52 [with absolute values for seven of the eight
(87.5 %) coefficients between 0.30 and 0.70, and absolute
values for the remaining one coefficient (12.5 %) at 0.30 or
below], with an average magnitude of 0.41 (0.34–0.48); and
the magnitude of correlation coefficients between changes
in WPAI:SHP scores and symptom measures ranged from
0.25 to 0.51 [with absolute values for seven of the eight
(87.5 %) coefficients between 0.30 and 0.70, and absolute
values for the remaining one coefficient (12.5 %) at 0.30 or
below], with an average magnitude of 0.40 (0.34–0.47).
Also observed was a difference in the strengths of associ-
ation across the two symptoms: the average magnitude of
the correlation among HRQL and WRO domain change
scores and changes in STF was 0.33 (0.27–0.36), while the
average magnitude among HRQL and WRO domain change
scores and changes in RBS was 0.39 (0.35–0.44).
Table 4 presents month 12 estimated mean SF-12v2,
SIBDQ, and WPAI:SHP domain scores (adjusted for
patients’ age, gender, BMI, and maintenance baseline
Table 1 Baseline patient characteristics and SF-12v2, SIBDQ, WPAI:SHP, and UC symptom scores for acute and maintenance phase samples
and subsamples
Acute phase
baseline (n = 132)
Maintenance phase
baseline (n = 206)
Maintenance phase baseline
for acute ? maintenance
phase subsample (n = 56)
Maintenance phase baseline
for maintenance phase-only
subsample (n = 150)
Age [mean (SD)] 43.4 (14.1) 46.9 (13.7) 42.9 (14.4) 48.4 (13.2)a
Female [n (%)] 74 (56.1 %) 106 (51.5 %) 27 (48.2 %) 79 (52.7 %)
Employed [n (%)] 84 (63.6 %) 150 (72.8 %) 42 (75.0 %) 108 (72.0 %)
SF-12v2 [mean (SD)]
Physical functioning 48.1 (10.1) 53.5 (6.8) 54.3 (4.4) 53.2 (7.5)
Role physical 44.8 (10.5) 52.8 (6.7) 53.0 (6.1) 52.7 (6.9)
Bodily pain 45.2 (11.3) 53.6 (7.2) 55.1 (6.1) 53.1 (7.4)
General health 44.6 (10.7) 51.8 (7.8) 52.4 (5.9) 51.5 (8.5)
Vitality 47.0 (10.3) 53.6 (8.5) 54.8 (8.8) 53.2 (8.4)
Social functioning 44.7 (12.4) 52.9 (7.3) 53.3 (7.0) 52.8 (7.4)
Role emotional 47.0 (10.7) 51.7 (7.3) 51.8 (7.5) 51.6 (7.2)
Mental health 48.1 (10.8) 53.1 (8.6) 54.3 (8.9) 52.7 (8.4)
Physical summary (PCS) 45.4 (9.8) 53.2 (6.5) 53.9 (4.4) 53.0 (7.1)
Mental summary (MCS) 47.3 (10.1) 52.3 (8.2) 53.0 (8.6) 52.1 (8.0)
SIBDQ [mean (SD)]
Bowel symptoms 12.8 (4.3) 18.5 (2.6) 18.6 (2.4) 18.4 (2.7)
Systemic symptoms 8.9 (3.0) 10.8 (2.5) 11.2 (2.6) 10.6 (2.6)
Emotional function 14.0 (4.3) 17.3 (3.0) 17.4 (3.3) 17.2 (2.9)
Social function 10.1 (3.4) 13.2 (1.5) 13.2 (1.5) 13.2 (1.5)
Total score 45.9 (12.9) 59.8 (7.7) 60.7 (7.5) 59.4 (7.8)
WPAI [mean (SD)]
Absenteeism 8.8 (21.1) 0.6 (3.5) 1.4 (5.9) 0.3 (1.7)
Presenteeism 27.5 (26.3) 5.1 (9.7) 5.2 (11.3) 5.1 (9.1)
Overall work impairment 30.0 (29.2) 5.5 (10.8) 6.1 (13.7) 5.3 (9.6)
Activity impairment 35.5 (31.2) 7.6 (14.1) 6.6 (14.4) 8.0 (14.0)
UC symptoms [mean (SD)]
Stool frequency 0.73 (0.69) 0.15 (0.33) 0.15 (0.38) 0.14 (0.31)
Rectal bleeding severity 0.88 (0.77) 0.02 (0.12) 0.02 (0.11) 0.03 (0.12)
SF-12v2 12-item Short-Form Health Survey, version 2, SIBDQ Short Inflammatory Bowel Disease Questionnaire, WPAI:SHP Work Productivity
and Activity Impairment: Specific Health Problem, UC ulcerative colitis, SD standard deviation
a P \ 0.05 for differences between acute ? maintenance phase and maintenance phase-only subsamples
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Table 2 Spearman coefficients for inter-domain correlations among acute phase baseline-endpoint SF-12v2, SIBDQ, and WPAI:SHP change
scores
SF-12v2 SIBDQ WPAI
PF RP BP GH VT SF RE MH BS SS EF Social Absent Present OWI
PF --
RP 0.40 --
BP 0.39 0.52 --
GH 0.32 0.36 0.25 --
VT 0.35 0.48 0.45 0.39 --
SF 0.43 0.41 0.52 0.33 0.42 --
RE 0.27 0.47 0.39 0.43 0.44 0.53 --
SF-12v2
MH 0.23 0.22 0.34 0.43 0.44 0.52 0.43 --
BS 0.28 0.47 0.54 0.34 0.47 0.38 0.39 0.24 --
SS 0.35 0.43 0.46 0.43 0.56 0.53 0.50 0.45 0.50 --
EF 0.28 0.32 0.37 0.30 0.40 0.49 0.49 0.70 0.43 0.49 --
SIBDQ
Social 0.42 0.54 0.58 0.28 0.44 0.65 0.50 0.35 0.64 0.49 0.52 --
Absent -0.22 -0.38 -0.52 -0.07 -0.33 -0.37 -0.35 -0.18 -0.47 -0.13 -0.15 -0.36 --
Present -0.28 -0.57 -0.54 -0.15 -0.31 -0.35 -0.46 -0.17 -0.68 -0.31 -0.40 -0.64 0.61 --
OWI -0.28 -0.57 -0.54 -0.12 -0.31 -0.36 -0.46 -0.17 -0.68 -0.31 -0.38 -0.63 0.68 0.99 --
WPAI
AI -0.35 -0.50 -0.55 -0.34 -0.44 -0.44 -0.41 -0.33 -0.55 -0.46 -0.49 -0.68 0.41 0.74 0.72
SF-12v2, 12-item Short-Form health survey, version 2; SIBDQ, Short Inflammatory Bowel Disease Questionnaire; WPAI:SHP, Work Productivity and Activity 
Impairment: Specific Health Problem; PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health perceptions; VT, vitality; SF, social 
functioning; RE, role emotional; MH, mental health; BS, bowel symptoms; SS, systemic symptoms; EF, emotional function; Social, social function; Absent, 
absenteeism; Present, presenteeism; OWI, overall work impairment; AI, activity impairment.
Bolded correlations: P <0.05.
Table 3 Spearman coefficients for correlations between acute phase baseline-endpoint SF-12v2, SIBDQ, and WPAI:SHP change scores and UC
symptom change scores
Stool frequency Rectal bleeding severity
UC symptoms Stool frequency – –
Rectal bleeding severity 0.52 (0.36, 0.65) –
SF-12v2 Physical functioning 20.25 (20.42, 20.05) 20.30 (20.47, 20.12)
Role physical 20.24 (20.42, 20.05) 20.30 (20.47, 20.12)
Bodily pain 20.33 (20.49, 20.15) 20.33 (20.50, 20.15)
General health 20.31 (20.47, 20.12) 20.28 (20.45, 20.09)
Vitality 20.29 (20.46, 20.11) 20.45 (20.59, 20.28)
Social functioning 20.34 (20.50, 20.15) 20.40 (20.55, 20.23)
Role emotional 20.24 (20.41, 20.05) 20.35 (20.51, 20.16)
Mental health -0.15 (-0.33, 0.05) 20.26 (20.44, 20.07)
SIBDQ Bowel symptoms 20.43 (20.58, 20.26) 20.52 (20.65, 20.37)
Systemic symptoms 20.35 (20.51, 20.17) 20.40 (20.55, 20.22)
Emotional function 20.26 (20.43, 20.07) 20.41 (20.56, 20.24)
Social function 20.37 (20.52, 20.18) 20.50 (20.63, 20.34)
WPAI:SHP Absenteeism 0.25 (0.01, 0.46) 0.38 (0.15, 0.57)
Presenteeism 0.38 (0.16, 0.57) 0.42 (0.20, 0.60)
Overall work impairment 0.36 (0.13, 0.55) 0.42 (0.20, 0.60)
Activity impairment 0.50 (0.33, 0.63) 0.51 (0.35, 0.64)
Lower and upper boundary values for 95 % CIs around correlation coefficients are in parenthesis
SF-12v2 12-item Short-Form Health Survey, version 2, SIBDQ Short Inflammatory Bowel Disease Questionnaire, WPAI:SHP Work Productivity
and Activity Impairment: Specific Health Problem
Bolded correlations are statistically different from 0 (P \ 0.05)
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value) between patients who did or did not exhibit clinical
recurrence at the end of the maintenance phase. The
majority of domains (i.e., all but the PF domain on the SF-
12v2, the SS domain on the SIBDQ, and the absenteeism
domain on the WPAI:SHP) indicated significantly worse
outcomes for patients with recurrent symptoms, P \ 0.05
for all differences. Effect sizes for SF-12v2 domains were
small to moderate, ranging from 0.30 (PF) to 0.60 (BP)
with an average effect size of 0.45 (95 % CI 0.39–0.51).
Average effect sizes for SIBDQ and WPAI:SHP were
negatively impacted by each having one domain showing
negligible group effects (d = 0.03 for the SIBDQ SS
domain, d = -0.06 for the WPAI:SHP absenteeism
domain); mean effect sizes across SIBDQ domains were
0.48 (0.14–0.82), ranging from 0.03 (SS) to 0.86 (BS); and
across WPAI:SHP domains were 0.41 (0.08–0.73), ranging
from -0.06 (absenteeism) to 0.71 (presenteeism).
Sensitivity of SF-12v2, SIBDQ, and WPAI:SHP
to acute treatment
Table 5 presents mean SF-12v2, SIBDQ, and WPAI:SHP
domain and summary scores at acute phase baseline and
8-week endpoint from patients who completed these
measures at both times. Comparison of scores between
visits using paired-sample t tests revealed statistically sig-
nificant improvements (P \ 0.05 for all differences) for 18
of the 19 domains and summary measures, with only the
RE domain of the SF12v2 showing no significant change
over time.
Examination of Cohen’s dz effect sizes for standardized
mean differences yielded different patterns of magnitude in
changes across the three instruments. Effect sizes for
changes in SIBDQ domains [which ranged from moderate
(0.44 for EF) to large (1.03 for BS); mean dz = 0.62, 95 %
CI 0.35–0.89] were generally larger than those observed for
SF-12v2 domains [which ranged from small (0.15 for RE)
to moderate (0.45 for BP); mean dz = 0.33, 95 % CI
0.27–0.39] and for WPAI:SHP domains [which ranged
from small (0.26 for absenteeism) to moderate (0.52 for
activity impairment); mean dz = 0.43, 95 % CI 0.32–0.54].
Discussion
Findings from the current study provide several pieces of
evidence regarding the correspondence among instruments
measuring different PROs, and between each of these PRO
Table 4 Comparison of estimated mean SF-12v2, SIBDQ, and WPAI:SHP Scores (adjusted for age, gender, BMI, and baseline value) at
12-month maintenance phase endpoint for patients with clinically recurrent or non-recurrent symptoms
Estimated mean (SE) for
non-recurrent patients (n = 117)
Estimated mean (SE) for




Physical functioning 53.8 (0.60) 51.3 (1.23) ns 0.30
Role physical 53.1 (0.66) 49.3 (1.34) \0.05 0.42
Bodily pain 53.5 (0.76) 47.4 (1.53) \0.001 0.60
General health 53.2 (0.71) 48.8 (1.43) \0.01 0.46
Vitality 53.9 (0.75) 48.6 (1.53) \0.01 0.52
Social functioning 52.8 (0.75) 48.6 (1.51) \0.05 0.41
Role emotional 52.8 (0.73) 49.0 (1.47) \0.05 0.39
Mental health 53.6 (0.70) 49.0 (1.43) \0.01 0.49
SIBDQ
Bowel symptoms 18.3 (0.28) 15.1 (0.58) \0.001 0.86
Systemic symptoms 10.9 (0.21) 11.0 (0.43) ns 0.03
Emotional function 17.6 (0.31) 15.8 (0.62) \0.01 0.46
Social function 13.2 (0.18) 11.8 (0.37) \0.001 0.58
WPAI:SHP
Absenteeism 2.4 (1.27) 1.5 (2.62) ns -0.06
Presenteeism 3.9 (1.70) 16.6 (3.34) \0.01 0.71
Overall work impairment 6.1 (2.10) 18.6 (4.35) \0.05 0.55
Activity impairment 7.5 (1.66) 16.7 (3.29) \0.05 0.43
SF-12v2 12-item Short-Form Health Survey, version 2, SIBDQ Short Inflammatory Bowel Disease Questionnaire, WPAI:SHP Work Productivity
and Activity Impairment: Specific Health Problem, BMI body mass index, SE standard error of the estimated mean, ns not statistically significant
a P values for comparison of means as a function of recurrence status were derived from analysis of covariance models with recurrence status as
a between-subjects factor, and patients’ age, gender, BMI, and baseline value on that domain as covariates
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instruments with measures of disease activity. Table 6
summarizes each of the six hypotheses tested in this ana-
lysis, as well as whether the findings were supportive or
non-supportive of the hypothesized relationships among
variables.
Consistent with our initial hypothesis, inter-domain
correlations for acute phase baseline-endpoint change
scores across SF-12v2, SIBDQ, and WPAI:SHP instru-
ments mostly ranged from 0.30 to 0.70, indicating gener-
ally moderate concordance in the improvement of each
outcome over time. The consistency in scores across
instruments also emerged from comparisons of scores
following treatment, with all but one domain (RE on the
SF-12v2) showing statistically significant improvement
from acute phase baseline to 8-week endpoint. Finally,
domains from all three of these instruments showed
improvement with decreases in stool frequency and rectal
bleeding during the acute phase, and all instruments were
generally sensitive to patient recurrent status at the main-
tenance phase endpoint.
While the central results of this analysis indicated close
correspondence among patient outcomes, several differ-
ences in their associations emerged that were consistent
with our hypotheses. Our second and third hypotheses,
which predicted that the association between SF-12v2 and
WPAI:SHP scores would be weaker than the associations
between SF-12v2 and SIBDQ scores (Hypothesis 2) and
weaker than associations between SIBDQ and WPAI:SHP
scores (Hypothesis 3), were both supported by the data.
Specifically, the average correlation coefficient between
changes in scores on the SF-12v2 and WPAI:SHP domains
from baseline to the 8-week endpoint in the acute phase
was smaller than for average correlations of change scores
across domains for either of the other two pairings.
Given that the SIBDQ, but not the SF-12v2, explicitly
probes the impact of symptoms on patients’ perceptions of
HRQL, we hypothesized that the SIBDQ would show
greater sensitivity to disease activity than the SF-12v2, as
indicated by stronger correlations with UC symptom scores
(Hypothesis 4) and better discrimination between patients
with clinically recurrent and non-recurrent status
(Hypothesis 5). The observed results supported Hypothesis
4: The magnitude of the average correlation coefficient
between UC symptom measures and SIBDQ domains
(0.41, 95 % CI 0.34–0.48) was approximately 0.11 larger
than that between symptoms and SF-12v2 domains (0.30,
Table 5 Comparison of Mean SF-12v2, SIBDQ, WPAI:SHP, and UC symptom scores from baseline to week 8 of the acute phase
N Baseline [mean (SE)] Week 8 [mean (SE)] Mean difference Pa Effect size (dz)
SF-12v2
Physical functioning 107 49.1 (0.88) 51.2 (0.76) 2.1 \0.01 0.27
Role physical 107 45.8 (0.95) 49.4 (0.85) 3.6 \0.001 0.40
Bodily pain 107 46.5 (1.01) 51.1 (0.95) 4.6 \0.001 0.45
General health 107 45.3 (1.03) 48.6 (0.91) 3.3 \0.01 0.32
Vitality 107 47.7 (0.99) 51.8 (0.90) 4.1 \0.001 0.38
Social functioning 107 45.7 (1.13) 49.4 (0.98) 3.7 \0.01 0.31
Role emotional 107 48.3 (0.90) 49.8 (0.93) 1.5 ns 0.15
Mental health 107 49.0 (0.97) 52.5 (0.93) 3.5 \0.001 0.36
PCS 107 46.4 (0.89) 49.8 (0.81) 3.4 \0.001 0.45
MCS 107 48.2 (0.91) 51.1 (0.88) 2.9 \0.01 0.29
SIBDQ
Bowel symptoms 103 13.2 (0.43) 17.2 (0.35) 4.0 \0.001 1.03
Systemic symptoms 103 9.2 (0.3) 10.6 (0.26) 1.4 \0.001 0.47
Emotional function 103 14.6 (0.41) 16.4 (0.37) 1.8 \0.001 0.44
Social function 103 10.5 (0.32) 12.1 (0.27) 1.6 \0.001 0.55
Total score 103 47.5 (1.24) 56.3 (1.05) 8.8 \0.001 0.79
WPAI:SHP
Absenteeism 70 6.8 (2.18) 2.8 (1.54) –4.0 \0.05 0.26
Presenteeism 69 25.2 (2.95) 12.9 (2.59) –12.3 \0.001 0.46
Work productivity 69 27.4 (3.25) 13.6 (2.71) –13.8 \0.001 0.47
Activity impairment 103 32.4 (2.97) 18.2 (2.54) –14.2 \0.001 0.52
SF-12v2 12-item Short-Form Health Survey, version 2, SIBDQ Short Inflammatory Bowel Disease Questionnaire, WPAI:SHP Work Productivity
and Activity Impairment: Specific Health Problem, BMI body mass index, SE standard error of the mean, ns not statistically significant
a P values for comparison of means between visits were derived from paired-sample t tests with a two-tailed test for statistical significance
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0.27–0.34). Results were not supportive of Hypothesis 5:
The average effect sizes for standardized mean differences
between recurrent and non-recurrent patients were of
similar magnitude for domain scores of the SIBDQ (aver-
age d = 0.48, 95 % CI 0.14–0.82), the SF-12v2 (average
d = 0.45, 0.39–0.51), and the WPAI:SHP (d = 0.41,
0.08–0.73). Interestingly, the inconsistency in findings
across these two analytic approaches is consistent with the
results reported by McColl et al. [25], who found that a
continuous measure of UC symptom activity was more
strongly correlated with IBDQ scores than with SF-36
scores, but that the IBDQ was not better than the SF-36 at
discriminating patients classified by disease extent.
While we expected all instruments to show improve-
ment over the course of treatment in the acute phase,
particularly given that improvement in SIBDQ and SF-
12v2 in this trial was previously established [19, 22], our
sixth hypothesis was that the SIBDQ would exhibit rela-
tively greater sensitivity to treatment than the SF-12v2
since, as a disease-specific measure, the SIBDQ should
more precisely capture the differences in HRQL related to
treatment for UC symptoms and their improvement as a
result of treatment. The data were generally supportive of
this hypothesis: The mean effect size for standardized
change in domain scores from baseline to endpoint was
considerably larger for the SIBDQ (average dz = 0.62,
95 % CI 0.35–0.89) than for the SF-12v2 (average
dz = 0.33, 0.27–0.39).
While all three instruments showed generally moderate
levels of correspondence, each instrument provides a
unique and important contribution to understanding the
impact of UC, and the effect of treatment for UC, on
patients’ lives. The SIBDQ, as would be expected for a
disease-specific measure, exhibited moderate-to-high
responsiveness to disease activity, thus providing a reliable
measure of treatment impact. The SF-12v2 showed mod-
erate responsiveness to disease activity, and as a generic
measure that is widely used across many studies and dis-
ease areas, it provides the opportunity for a contextual
interpretation of the HRQL of patients with UC by facili-
tating comparisons with other disease samples and general
population norms to understand the burden of UC and the
degree to which this burden can be relieved through
treatment. The WPAI:SHP, with the exception of the
Table 6 Summary of hypotheses tested
Number Statement of hypothesis Reasoning underlying hypothesis Hypothesis supported by findings?
1 Most inter-domain correlations between
PRO instruments will be moderately
sized (i.e., falling within the range of
0.30–0.70)
Findings from prior research Yes; 65 of 80 (81 %) of inter-domain
correlations were within this range
2 Correlations between SF-12v2 and SIBDQ
domains will be larger than between SF-
12v2 and WPAI:SHP domains
The SF-12v2 and SIBDQ measure the
same underlying construct (HRQL),
while the WPAI:SHP measures a
different construct (WRO)
Yes; the magnitude of the average inter-
domain correlation between SF-12v2 and
SIBDQ (0.44) was higher than between
SF-12v2 and WPAI:SHP (-0.37)
3 Correlations between SIBDQ and
WPAI:SHP domains will be larger than
between SF-12v2 and WPAI:SHP
domains
The SIBDQ and WPAI:SHP measure UC-
specific health outcomes, while the SF-
12v2 measures generic health outcomes
Yes; the magnitude of the average inter-
domain correlation between SIBDQ and
WPAI:SHP (0.47) was higher than
between SF-12v2 and WPAI:SHP (0.37)
4 Changes in UC symptoms from baseline to
week 8 will correlate more highly with
SIBDQ and WPAI:SHP domains than
with SF-12v2 domains
Because the SIBDQ and WPAI:SHP
measure UC-specific health outcomes,
while the SF-12v2 measures generic
health outcomes, the former two
instruments should be more responsive to
changes in UC-specific symptoms
Yes; the magnitude of the average
correlations of UC symptom scores with
domains of the SIBDQ (0.41) and
WPAI:SHP (0.40) was higher than
between UC symptom scores and SF-
12v2 domains (0.30)
5 Differences in change scores as a function
of month 12 clinical recurrence status
will be larger for SIBDQ and WPAI:SHP
domains than for SF-12v2 domains
Because the SIBDQ and WPAI:SHP
measure UC-specific health outcomes,
while the SF-12v2 measures generic
health outcomes, the former two
instruments should be more responsive to
changes in UC-specific symptoms
No; the magnitude of average effect sizes
for differences in domain scores between
clinical recurrence status groups was
similar across all PRO instruments (0.48
for SIBDQ, 0.45 for SF-12v2, and 0.44
for the WPAI:SHP)
6 SIBDQ and WPAI:SHP domains will
show larger treatment effects during the
acute treatment phase than will SF-12v2
domains
Because the SIBDQ and WPAI:SHP
measure UC-specific health outcomes,
while the SF-12v2 measures generic
health outcomes, the former two
instruments should be more sensitive to
treatment that decreases UC-specific
symptoms
Yes; the magnitude of average effect size
for changes in scores from Baseline to
week 8 was larger for domains of the
SIBDQ (average d = 0.62) and
WPAI:SHP (0.43) than for SF-12v2
domains (0.33)
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absenteeism domain, which was also moderately respon-
sive to changes in disease activity, allows for the most
instrumental interpretation of the impact of UC on patients’
lives.
Conclusion
The findings of mostly moderate correlations among scores
on the SF-12v2, SIBDQ, and WPAI:SHP, and between
each of these instruments and clinical symptoms, as well as
parallel responses to acute and maintenance MMX mesal-
amine daily treatment, indicate the consistency and corre-
spondence of these instruments within this UC patient
population. The finding that all three of these instruments
demonstrated sensitivity to treatment and responsiveness to
disease activity, with some predictable variations, and the
fact that the types of outcomes captured by the instruments
are complementary in terms of the interpretation they
afford indicate that it is appropriate and beneficial to
administer all three of these instruments (or any combi-
nation of these instruments depending upon the objectives
of the study) for the purpose of capturing the burden of UC
and the impact of treatment on quality of life and/or work-
related activities in clinical and outcomes research.
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